This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
To accelerate the development of next-generation radioconjugates to treat cancer
Mungara has over 25+ years of experience in the supply chain domain
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
From only 80 Jan Aushadhi Kendras in 2014, there are around 11,000 units operating across the country today
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
These approvals mark significant progress for Venus Remedies in expanding its market presence
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
Subscribe To Our Newsletter & Stay Updated
